Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide versus insulin detemir for diabetic kidney disease over 28 weeks
ChiCTR2400080751Phase 4Completed
- Sponsor
- Zhu Xianyi Memorial Hospital
- Start
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of semaglutide in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Zhu Xianyi Memorial Hospital. Primary endpoints: Serum creatinine, Estimated glomerular filtration rate and 8 more. Started Feb 2024; status: completed.
02
Drugs
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400080751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080751.